This is a StreetInsider.com Premium Only Page

Opiant Pharmaceuticals (OPNT) – StreetInsider.com Reports

Feb 7, 2023 04:02 PM Opiant Pharmaceuticals (OPNT) Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

Feb 6, 2023 08:00 AM Opiant Pharmaceuticals (OPNT) Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

Jan 19, 2023 04:05 PM Opiant Pharmaceuticals (OPNT) Announces FDA Acceptance and Priority Review of NDA for OPNT003

Nov 23, 2022 09:08 AM Northland Capital Markets Downgrades Opiant Pharma (OPNT) to Market Perform

Nov 22, 2022 04:04 PM Opiant Pharmaceuticals (OPNT) Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

Nov 22, 2022 01:33 PM Cantor Fitzgerald Downgrades Opiant Pharma (OPNT) to Neutral on Acqusition

Nov 22, 2022 01:33 PM Cantor Fitzgerald Downgrades Opiant Pharma (OPNT) to Neutral

Nov 14, 2022 02:06 PM Oppenheimer Downgrades Opiant Pharma (OPNT) to Perform

Nov 14, 2022 07:42 AM Opiant Pharma (OPNT) PT Lowered to $22 at Northland Capital Markets

Nov 14, 2022 05:40 AM Opiant Pharmaceuticals (OPNT) Acquired by Indivior for up To $28/sh

Aug 22, 2022 04:10 PM Opiant Pharmaceuticals (OPNT) Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004

Aug 2, 2022 04:06 PM Opiant Pharmaceuticals (OPNT) Granted US Patent With Claims Covering OPNT003

Jun 8, 2022 04:07 PM Opiant Pharmaceuticals (OPNT) Expands Collaboration with Antar Pharma to Manufacture Unidose Nasal Spray for OPNT003

Jun 1, 2022 04:07 PM Opiant Pharmaceuticals (OPNT) Announces Rolling Submission of NDA for OPNT003

May 11, 2022 08:16 AM Opiant Pharma (OPNT) PT Lowered to $41 at Oppenheimer

May 10, 2022 05:01 PM Opiant Pharmaceuticals (OPNT) Posts Wider Q1 Loss

Apr 29, 2022 12:48 PM Opiant Pharmaceuticals (OPNT) Responds to "Fake Press Release"

Apr 29, 2022 10:39 AM Opiant Pharmaceuticals (OPNT) Halted, News Pending

Apr 27, 2022 04:04 PM Opiant Pharmaceuticals (OPNT) Reports Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003 to Nasal Naloxone

Apr 27, 2022 05:55 AM Veru (VERU) and Opiant (OPNT) Top Cantor Fitzgerald's List of Largest Short Interest Increases

Mar 16, 2022 06:06 AM Oppenheimer Reiterates Opiant Pharma (OPNT) at Outperform Following Earnings

Mar 15, 2022 04:08 PM Opiant Pharmaceuticals (OPNT) Tops Q4 EPS by 18c

Feb 14, 2022 05:54 AM Oppenheimer Reiterates Outperform Rating on Opiant Pharma (OPNT), "Expect Upcoming Data to Illustrate Advantage for OPNT003"

Feb 10, 2022 08:09 AM Opiant Pharmaceuticals (OPNT) Reports Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003

Feb 10, 2022 08:01 AM Opiant Pharmaceuticals (OPNT) Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene

Feb 8, 2022 12:51 PM Opiant Pharmaceuticals (OPNT) on Watch on Chatter

Jan 24, 2022 04:05 PM Opiant Pharmaceuticals (OPNT) Announces Additional $2.2M Funding Under BARDA Contract for OPNT003

Dec 9, 2021 09:29 AM Pre-Open Stock Movers 12/09: (IINN) (AVCT) (RH) Higher; (RETA) (RLMD) (GME) Lower (more...)

Dec 8, 2021 05:10 PM After-Hours Stock Movers 12/08: (RH) (STRM) (APTX) Higher; (RLMD) (GME) (LCID) Lower (more...)

Dec 8, 2021 04:06 PM Oppenheimer Starts Opiant Pharma (OPNT) at Outperform

Nov 11, 2021 04:07 PM Opiant Pharmaceuticals (OPNT) Tops Q3 EPS by 85c

Nov 4, 2021 04:08 PM Opiant Pharmaceuticals (OPNT) Granted FDA Fast Track Designation for OPNT003

Aug 13, 2021 04:37 PM Opiant Pharmaceuticals (OPNT) Files for Up to $100M Share & Warrant Offering

Jul 7, 2021 09:26 AM Pre-Open Stock Movers 07/07: (DARE) (OPNT) (BHVN) Higher; (BSQR) (IDYA) (LOAN) Lower (more...)

Jul 6, 2021 06:03 PM After-Hours Stock Movers 07/06: (OPNT) (IMMR) (CFMS) Higher; (IDYA) (LOAN) (EFC) Lower (more...)

Jul 6, 2021 04:39 PM Opiant Pharmaceuticals (OPNT) Announces Positive Top-line Results of Confirmatory Pharmacokinetic Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose

May 11, 2021 04:38 PM Opiant Pharmaceuticals (OPNT) Tops Q1 EPS by 5c, Revenues Beat

Apr 5, 2021 04:01 PM Opiant Pharmaceuticals (OPNT) Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone

Mar 4, 2021 04:31 PM Opiant Pharmaceuticals (OPNT) Misses Q4 EPS by 23c, Revenues Beat

Dec 14, 2020 04:01 PM Opiant Pharmaceuticals (OPNT) Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

Dec 10, 2020 04:04 PM Opiant Pharmaceuticals (OPNT) Secures $50 Million in Convertible Debt Financing

Dec 7, 2020 04:03 PM Opiant Pharmaceuticals (OPNT) Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors

Nov 12, 2020 04:35 PM Opiant Pharmaceuticals (OPNT) Tops Q3 EPS by 36c, Revenues Beat

Jun 16, 2020 07:04 AM Companies with NDRs 6/16

Jun 15, 2020 07:21 AM Companies with NDRs 6/15

May 12, 2020 04:21 PM Opiant Pharmaceuticals (OPNT) Misses Q1 EPS by 22c, Revenues Miss

Mar 4, 2020 04:09 PM Opiant Pharmaceuticals (OPNT) Tops Q4 EPS by $2.30

Jan 2, 2020 08:02 AM Opiant Pharmaceuticals (OPNT) Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdo

Nov 12, 2019 04:32 PM Opiant Pharmaceuticals (OPNT) Tops Q3 EPS by $2.06, Revenues Beat

Aug 8, 2019 05:21 PM Opiant Pharmaceuticals (OPNT) Tops Q2 EPS by 86c, Revenues Beat